Mixed Results In AZ's DECLARE-TIMI 58 CV Trial Cloud Implications For Farxiga

 
• By Sten Stovall

While clarification on mixed DECLARE-TIMI 58 CV top-line data in diabetes patients is awaited at November's AHA meeting AstraZeneca says it is confidently pursuing independent studies of its SGLT-2 inhibitor Farxiga in heart failure and kidney disease patients.

Heart
Farxiga showed mixed results in Its Phase III DECLARE-TIMI 58 CV Trial • Source: Shutterstock

More from Clinical Trials

More from R&D